CDTX is pushing higher today after being initiated at Aegis Capital today as a Buy. Analysts gave the stock a price target of $9, which is just shy of the high estimate for $10. This new rating is a reiteration of market sentiment toward Cidara Therapeutics, which has been increasingly bullish.
Full Answer
Where can I buy shares of CDTX?
Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How much did CDTX raise in its IPO?
(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share.
What is Cidara Therapeutics'(CDTX) stock worth?
Since then, CDTX stock has decreased by 32.7% and is now trading at $1.67. View which stocks have been most impacted by COVID-19. When is Cidara Therapeutics' next earnings date? Cidara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022. View our earnings forecast for Cidara Therapeutics.
Is CDTX stock a good buy?
The consensus among 3 Wall Street analysts covering (NASDAQ: CDTX) stock is to Strong Buy CDTX stock.
Is Cidara a buy?
Cidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Should I buy or sell Cidara Therapeutics stock right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last twelve months. There are currently 4 buy r...
What is Cidara Therapeutics' stock price forecast for 2022?
5 Wall Street research analysts have issued 12-month target prices for Cidara Therapeutics' stock. Their forecasts range from $6.00 to $8.00. On av...
How has Cidara Therapeutics' stock performed in 2022?
Cidara Therapeutics' stock was trading at $1.27 at the start of the year. Since then, CDTX shares have decreased by 57.5% and is now trading at $0....
When is Cidara Therapeutics' next earnings date?
Cidara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for...
How were Cidara Therapeutics' earnings last quarter?
Cidara Therapeutics, Inc. (NASDAQ:CDTX) announced its quarterly earnings results on Wednesday, May, 11th. The biotechnology company reported ($0.27...
Who are Cidara Therapeutics' key executives?
Cidara Therapeutics' management team includes the following people: Dr. Jeffrey L. Stein Ph.D. , Pres, CEO & Exec. Director (Age 67, Pay $836.4k...
Who are some of Cidara Therapeutics' key competitors?
Some companies that are related to Cidara Therapeutics include Poseida Therapeutics (PSTX) , Taysha Gene Therapies (TSHA) , CEL-SCI (CVM) , CEL...
What other stocks do shareholders of Cidara Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceu...
When did Cidara Therapeutics IPO?
(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 p...
Is Cidara Therapeutics stock a Buy, Sell or Hold?
Cidara Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 2 buy ratings, 0 hold ratings, and 0...
What was the 52-week low for Cidara Therapeutics stock?
The low in the last 52 weeks of Cidara Therapeutics stock was 0.41. According to the current price, Cidara Therapeutics is 108.27% away from the 52...
What was the 52-week high for Cidara Therapeutics stock?
The high in the last 52 weeks of Cidara Therapeutics stock was 2.36. According to the current price, Cidara Therapeutics is 18.81% away from the 52...
What are analysts forecasts for Cidara Therapeutics stock?
The 2 analysts offering price forecasts for Cidara Therapeutics have a median target of 5.50, with a high estimate of 6.00 and a low estimate of 5....
Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should Know
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Clears Cidara Therapeutics' Phase 1 Trial For Immunotherapeutic Antiviral For Influenza
The FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza, added the Company.
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza
Cidara intends to initiate the Phase 1 trial in Q1 2022 Drug-Fc conjugate (DFC) CD388 leverages Cidara’s Cloudbreak® platform and has the potential to offer significant advantages over current flu vaccines in a single seasonal dose SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc.
When will Cidara be available in 2021?
(NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31 st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021 .
What is Cidara Therapeutics?
Cidara Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014.
Is Cidara Therapeutics a biotechnology company?
SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 172,000 shares of its common stock to eight new employees, pursuant to the Cidara Therapeut
How Does Total Compensation For Jeff Stein Compare With Other Companies In The Industry?
Our data indicates that Cidara Therapeutics, Inc. has a market capitalization of US$100m, and total annual CEO compensation was reported as US$1.3m for the year to December 2020. Notably, that's a decrease of 11% over the year before. While we always look at total compensation first, our analysis shows that the salary component is less, at US$542k.
Cidara Therapeutics, Inc.'s Growth
Over the past three years, Cidara Therapeutics, Inc. has seen its earnings per share (EPS) grow by 31% per year. It saw its revenue drop 49% over the last year.
Has Cidara Therapeutics, Inc. Been A Good Investment?
The return of -60% over three years would not have pleased Cidara Therapeutics, Inc. shareholders. This suggests it would be unwise for the company to pay the CEO too generously.
To Conclude..
Shareholders have not seen their shares grow in value, rather they have seen their shares decline. A huge lag in share price growth when earnings have grown may indicate there could be other issues that are affecting the company at the moment that the market is focused on.